34-Year-Old Man Presents With a Soft Tissue Induration in the Right Thigh

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Benjamin J. Golas, MD

June 30th 2025

3 Things You Should Know About Targeting NRG1 and Rare Drivers in Pancreatic Cancer

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Explore the latest advancements in pancreatic cancer treatment, focusing on genetic mutations, targeted therapies, and emerging clinical strategies.

ONCOLOGY Staff

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Explore the latest advancements in pancreatic cancer treatment, focusing on genetic mutations, targeted therapies, and emerging clinical strategies.

Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Stephen V. Liu, MD;Joshua K. Sabari, MD

June 23rd 2025

SonoClear System Earns Breakthrough Designation for Intracranial Procedures

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

The system showed enhanced diagnostic accuracy of intraoperative imaging, potentially improving the extent of resection while reducing residual disease.

Zanidatamab Receives EU Conditional Marketing Authorization in HER2+ BTC

The system showed enhanced diagnostic accuracy of intraoperative imaging, potentially improving the extent of resection while reducing residual disease.

Data from the HERIZON-BTC-01 trial evaluating zanidatamab in previously treated, unresectable HER2-positive biliary tract cancer support the decision.

16 A Miami Hospital’s Infrastructure to Help Decrease Late-Stage Breast Cancer Diagnosis and Improve Health Equity

Data from the HERIZON-BTC-01 trial evaluating zanidatamab in previously treated, unresectable HER2-positive biliary tract cancer support the decision.

Related Content

Yolcar Chamorro;Ana Sandoval Leon, MD;Cynthia Thiry;Barbara Gallo;Sherine Mitchell;Alejandro Larios Venegas

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD

June 30th 2025

3 Things You Should Know About Targeting NRG1 and Rare Drivers in Pancreatic Cancer

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

ONCOLOGY Staff

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Explore the latest advancements in pancreatic cancer treatment, focusing on genetic mutations, targeted therapies, and emerging clinical strategies.

Stephen V. Liu, MD;Joshua K. Sabari, MD

June 23rd 2025

SonoClear System Earns Breakthrough Designation for Intracranial Procedures

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Zanidatamab Receives EU Conditional Marketing Authorization in HER2+ BTC

The system showed enhanced diagnostic accuracy of intraoperative imaging, potentially improving the extent of resection while reducing residual disease.